Effect of Helicobacter pylori infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer vol. 25 (2025), p. 1
Autor principal: Qi-Chen, He
Otros Autores: Huang, Ze-Ning, Chen-Bin, Lv, Yong-He, Wu, Wen-Wu, Qiu, Yu-Bin, Ma, Wu, Ju, Chang-Yue, Zheng, Guo-Sheng, Lin, Li, Ping, Jia-Bin, Wang, Jian-Xian Lin, Lin, Mi, Ru-Hong Tu, Chao-Hui, Zheng, Chang-Ming, Huang
Publicado:
Springer Nature B.V.
Materias:
Acceso en línea:Citation/Abstract
Full Text
Full Text - PDF
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

MARC

LEADER 00000nab a2200000uu 4500
001 3187548907
003 UK-CbPIL
022 |a 1471-2407 
024 7 |a 10.1186/s12885-025-13840-7  |2 doi 
035 |a 3187548907 
045 2 |b d20250101  |b d20251231 
084 |a 58465  |2 nlm 
100 1 |a Qi-Chen, He 
245 1 |a Effect of <i>Helicobacter pylori</i> infection on survival outcomes of patients undergoing radical gastrectomy after neoadjuvant chemotherapy: a multicenter study in China 
260 |b Springer Nature B.V.  |c 2025 
513 |a Journal Article 
520 3 |a BackgroundNeoadjuvant chemotherapy (NAC) has been confirmed to improve the prognosis of patients with advanced gastric cancer (AGC). However, no study has investigated whether Helicobacter pylori (HP) infection affects the postoperative survival of patients who receive NAC.MethodsThis retrospective cohort study included 307 patients with AGC who underwent laparoscopic radical gastrectomy after NAC at three hospitals in China between January 1, 2016, and April 31, 2020. Cox regression was used to assess prognostic factors for survival. Kaplan–Meier was used for survival analysis.ResultsThe HP + and the HP- group included 141 and 166 cases. The 3-year overall survival (OS) and disease-free survival (DFS) of the HP + group were significantly better than the HP- group (3-year OS: 75.9% vs. 60.2%, 3-year DFS: 70.2% vs. 52.3%; All P < 0.001). For the HP + group, ypTNM Stage III (HR, 4.00; 95% CI, 1.11–14.39; P = 0.034), NAC ≥ 4 cycles (HR, 0.43; 95% CI, 0.20–0.90; P = 0.026), and adjuvant chemotherapy (AC) ≥ 4 cycles (HR, 0.20; 95% CI, 0.09–0.48; P < 0.001) are independent prognostic factors for OS. In the cohort of HP + patients who received ≥ 4 cycles of NAC, the prognosis of patients who received ≥ 4 cycles of AC after surgery was better than that of patients who received < 4 cycles of AC (3-year OS: 92.5% vs 71.4%; P = 0.042).ConclusionsFollowing NAC, HP + patients with AGC exhibit better prognosis than that of HP- counterparts. For potentially resectable HP + AGC patients, radical surgery following ≥ 4 cycles of NAC with ≥ 4 cycles of sequential AC might be recommended to improve survival. 
651 4 |a China 
653 |a Infections 
653 |a Patients 
653 |a Gastrointestinal surgery 
653 |a Laparoscopy 
653 |a Medical prognosis 
653 |a Cancer therapies 
653 |a Prognosis 
653 |a Cohort analysis 
653 |a Surgery 
653 |a Hospitals 
653 |a Gastrectomy 
653 |a Gastric cancer 
653 |a Survival 
653 |a Chemotherapy 
653 |a Helicobacter pylori 
700 1 |a Huang, Ze-Ning 
700 1 |a Chen-Bin, Lv 
700 1 |a Yong-He, Wu 
700 1 |a Wen-Wu, Qiu 
700 1 |a Yu-Bin, Ma 
700 1 |a Wu, Ju 
700 1 |a Chang-Yue, Zheng 
700 1 |a Guo-Sheng, Lin 
700 1 |a Li, Ping 
700 1 |a Jia-Bin, Wang 
700 1 |a Jian-Xian Lin 
700 1 |a Lin, Mi 
700 1 |a Ru-Hong Tu 
700 1 |a Chao-Hui, Zheng 
700 1 |a Chang-Ming, Huang 
773 0 |t BMC Cancer  |g vol. 25 (2025), p. 1 
786 0 |d ProQuest  |t Health & Medical Collection 
856 4 1 |3 Citation/Abstract  |u https://www.proquest.com/docview/3187548907/abstract/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text  |u https://www.proquest.com/docview/3187548907/fulltext/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch 
856 4 0 |3 Full Text - PDF  |u https://www.proquest.com/docview/3187548907/fulltextPDF/embedded/7BTGNMKEMPT1V9Z2?source=fedsrch